InspireMD declared continuing constructive results from the MGuard™ Coronary Stent First-in-Man, multi-center current effort in Germany. This think aims at establishing the country and effectualness of MGuard™ Coronary Stent in broad venture patients with Byzantine lesions. The think direct modify saucer demonstrated 0% field inauspicious cardiac events (MACE) after 30 life in 60 patients, with 100% procedural success rate.

Tags: Risk, Success Rate